Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-08-03
2011-10-25
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S236000
Reexamination Certificate
active
08044049
ABSTRACT:
The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof.A compound represented by the formula (I):wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.
REFERENCES:
patent: 7723336 (2010-05-01), Vaccaro et al.
patent: 2010/0216798 (2010-08-01), Nakai et al.
patent: 1 153 920 (2001-11-01), None
patent: 1 415 987 (2004-05-01), None
patent: 8-20584 (1996-01-01), None
patent: 89/01333 (1989-02-01), None
patent: 89/01478 (1989-02-01), None
patent: 98/35958 (1998-08-01), None
patent: 00/42012 (2000-07-01), None
patent: 00/43366 (2000-07-01), None
patent: 01/32651 (2001-05-01), None
patent: 01/60814 (2001-08-01), None
patent: 02/32872 (2002-04-01), None
patent: 2005/066177 (2005-07-01), None
patent: 2007/013673 (2007-02-01), None
patent: 2008/016131 (2007-02-01), None
patent: 2007/025090 (2007-03-01), None
patent: 2007/025540 (2007-03-01), None
patent: 2007/038314 (2007-04-01), None
Barlin, et al., Austral. J. Chem. (1996), 49(4), 443-449 [Barlin (III)].
Stanovnik, et al., Tetrahedron (1967), 23(1), 387-95.
Registry Compound, Oct. 2008.
Bullock, et al., “Structural Basis of Inhibitor Specificity of the Human Protooncogene Proviral Insertion Site in Moloney Murine Leukemia Virus (PIM-1) Kinase”, J. Med. Chem. 2005, 48, 7604-7614.
Mourad, et al., “Synthesis of Imidazo[1,2-b]pyridazines: Fenbendazole, Oxifenbendazole Analogs and Related Derivatives”, J. Heterocyclic Chem., 30, 1365-1372, Oct.-Nov. 1993.
Barlin, et al., “Imidazo[1,2-b]pyridazines. II 6-Alkylthio- and 6-Arylthio-3-methoxy- 2-phenylimidazo [1,2-b-]pyridazines” Aust. J. Chem., 1987, 40, 1491-7.
Barlin, et al., “Imidazo[1,2-b]pyridazlines IV Syntheses and Central Nervous System Activities of Some 3-Methoxy-6-phenoxy(substituted phenoxy and naphthylocy)-2-phenylimidazo[1,2-b]pyridazines”, Aust. J. Chem, 1988, 41, 1735-42.
Treb{hacek over (s)}e, et al., “A Direct Conversion of 5,6,7,8-Tetrahydro-2H-1-Benzo-Pyran-2,5-Diones into Substituted 1-Amion-5,6,7,8-Tetra-Hydroquinoline-2,5-Diones”, Heterocycles, vol. 59, No. 1, 129-136, 2003.
Treb{hacek over (s)}e, et al., “Transformation of 5-Oxo Substituted Fused Pyran-2-ones. LactamVersusHydrazone Formation”, Synthetic Communications, 27(15), 2637-2644, 1997.
Goli{hacek over (c)} Grdadolnik, et al., “Structural Investigation of 5-Hydrazono-5,6,7,8-tetrahydro-2H-1-benzopyran-2-ones and 5,6,7,8-Tetrahydroquinoline-2,5(1H)-diones”, J. Chem. Inf. Comput. Sci. 1997, 37, 489-494.
Ishikawa, et al., “Synthesis and Antibacterial Activity of 7 β-[2-(5-Amino-1,2,4-thiadiazol-3-y1)-2(Z)- alkoxyiminoacetamido]-3-[(E)-2-(1-alkylimidazo[1,2-b]pyridazinium-6-yl)thiovinyl]-3-cephem-4-carboxylates and Related Compounds”, The Journal of Antibiotics, 54(3), 257-277, Mar. 2001.
Matter. Alex, “Tumor angiogenesis as a therapeutic target”, DDT vol. 6, No. 19, Oct. 2001, pp. 1005-1024.
Ferrara, et al., “The Biology of Vascular Endothelial Growth Factor”, Endocrine Reviews, vol. 18, No. 1, Feb. 1997, pp. 4-25.
Folkamn, Judah, “Tumor Angiogenesis: Therapeutic Implications, The New England Journal of Medicine”, vol. 285, No. 21, Nov. 1971, pp. 1182-1186.
Hirayama Takaharu
Imamura Shinichi
Miyamoto Naoki
Sakai Nozomu
Hamre Schumann Mueller & Larson P.C.
Jaisle Cecilia M
Takeda Pharmaceutical Company Limited
Wilson James O
LandOfFree
Fused heterocyclic derivative and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused heterocyclic derivative and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic derivative and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4282406